Unmet needs in histological transformation of follicular lymphoma: a clinical and biological review

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  2017-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.21037/AOL.2017.11.03
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome

  2017cited by this paper
• Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy.

  2017cited by this paper
• PATIENTS WITH FOLLICULAR LYMPHOMA (FL) IN MAINTAINED COMPLETE RESPONSE (CR) AT 30 MONTHS SHOW A SURVIVAL SIMILAR TO A SEX‐ AND AGE‐MATCHED SPANISH GENERAL POPULATION

  2017cited by this paper
• From Waldenström’s macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation

  2017cited by this paper
• HIGH RESPONSE RATES WITH PEMBROLIZUMAB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: INTERIM RESULTS OF AN ON OPEN‐LABEL, PHASE II STUDY

  2017cited by this paper
• THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE

  2017influential reference
• IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN

  2017cited by this paper
• Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013

  2017influential reference
• Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group

  2017influential reference
• Transformation of marginal zone lymphoma (and association with other lymphomas).

  2017cited by this paper
• Can histologic transformation of follicular lymphoma be predicted and prevented?

  2017cited by this paper
• Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

  2016cited by this paper
• Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study

  2016influential reference
• Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.

  2016influential reference
• Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma

  2016cited by this paper
• Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.

  2016cited by this paper
• Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

  2015cited by this paper
• Treatment of patients with transformed lymphoma.

  2015cited by this paper
• Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

  2015cited by this paper
• Histologic transformation in marginal zone lymphomas†.

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation.

  2015cited by this paper
• Cell of origin of transformed follicular lymphoma.

  2015cited by this paper
• Transformed follicular non-Hodgkin lymphoma.

  2015influential reference
• Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.

  2015cited by this paper
• Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

  2015cited by this paper
• A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.

  2015cited by this paper
• Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis

  2014cited by this paper
• Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.

  2014influential reference
• Genetics of follicular lymphoma transformation.

  2014influential reference
• Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

  2014cited by this paper
• PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

  2014cited by this paper
• Survival analysis in hematologic malignancies: recommendations for clinicians

  2014cited by this paper
• MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma

  2014cited by this paper
• Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.

  2014cited by this paper
• Molecular bases of chronic lymphocytic leukemia in light of new treatments.

  2013cited by this paper
• Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma

  2013influential reference
• Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

  2013cited by this paper
• Analysis of FOXO1 mutations in diffuse large B-cell lymphoma.

  2013cited by this paper
• Richter syndrome.

  2013cited by this paper
• Transformed non‐Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database

  2013cited by this paper
• The World Health Organization Classification of Lymphoid Neoplasms

  2013cited by this paper
• Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.

  2013influential reference
• Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.

  2013cited by this paper
• Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.

  2013cited by this paper
• HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma.

  2013cited by this paper
• Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

  2012cited by this paper
• Superior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantation.

  2012cited by this paper
• EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

  2012cited by this paper
• Pathogenesis of follicular lymphoma.

  2012cited by this paper
• High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era

  2012cited by this paper
• Incidence, risk factors and outcome of histological transformation in follicular lymphoma

  2012cited by this paper
• The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non‐Hodgkin lymphoma of distinct histological origin

  2011cited by this paper
• Transformation of indolent B-cell lymphomas.

  2011cited by this paper
• GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and Suggests Shared Genetic Susceptibility with Diffuse Large B-cell Lymphoma

  2011cited by this paper
• Frequent mutation of histone modifying genes in non-Hodgkin lymphoma

  2011cited by this paper
• Transformation of follicular lymphoma.

  2011cited by this paper
• Human Leukocyte Antigen Class I and II Alleles and Overall Survival in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

  2011cited by this paper
• Association of HLA-DQB1 alleles with risk of follicular lymphoma

  2011cited by this paper
• CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

  2011cited by this paper
• SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma

  2011cited by this paper
• Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

  2011cited by this paper
• SNP rs6457327 is a predictor for overall survival in follicular lymphoma as well as survival after transformation.

  2011cited by this paper
• The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation.

  2010cited by this paper
• Vascularization predicts overall survival and risk of transformation in follicular lymphoma

  2010cited by this paper
• Cancer esearch cular and Cellular Pathobiology uired TNFRSF 14 Mutations in Follicular Lymphoma Are R ociated with Worse Prognosis

  2010cited by this paper
• Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy.

  2010cited by this paper
• Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones.

  2010cited by this paper
• Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma

  2010cited by this paper
• Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32

  2010cited by this paper
• Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology.

  2010cited by this paper
• Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma.

  2010cited by this paper
• Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols

  2009cited by this paper
• Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma

  2009cited by this paper
• High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma

  2009cited by this paper
• Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.

  2009cited by this paper
• Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma

  2008influential reference
• Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results

  2008cited by this paper
• Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.

  2008cited by this paper
• Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma

  2008cited by this paper
• High‐dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B‐cell lymphoma

  2008cited by this paper
• Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma

  2008cited by this paper
• The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival.

  2008cited by this paper
• The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL).

  2008cited by this paper
• Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.

  2008cited by this paper
• Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP.

  2008cited by this paper
• Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

  2008cited by this paper
• High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.

  2008cited by this paper
• Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma.

  2007cited by this paper
• Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma.

  2007influential reference
• A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.

  2007cited by this paper
• Transformation of follicular lymphoma to diffuse large B‐cell lymphoma proceeds by distinct oncogenic mechanisms

  2007cited by this paper
• A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone

  2007cited by this paper
• WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

  2007cited by this paper
• The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma.

  2006cited by this paper
• The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma.

  2006influential reference
• Role of fluorine‐18 fluoro‐deoxyglucose positron emission tomography scan in the evaluation and follow‐up of patients with low‐grade lymphomas

  2006cited by this paper
• Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.

  2005cited by this paper

• Identification of the histologic transformation of follicular lymphoma using super-resolution microcirculation imaging

  2025cites this paper
• Anlotinib suppresses the DNA damage response by disrupting SETD1A and inducing p53-dependent apoptosis in Transformed Follicular Lymphoma

  2024cites this paper
• Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review

  2024cites this paper
• Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas

  2019cites this paper